SpliSense

SpliSense is a clinical-stage biotechnology company focused on developing transformative RNA-based therapies for pulmonary diseases. The company utilizes a proprietary platform based on Antisense Oligonucleotides (ASOs) to target the root cause of genetic and pulmonary illnesses by restoring or modifying protein functionality. Its primary focus is on cystic fibrosis (CF), specifically addressing splicing mutations in the CFTR gene that are not adequately treated by existing modulators. Beyond CF, the company is expanding its pipeline to address other muco-obstructive diseases, including COPD, asthma, non-CF bronchiectasis, and idiopathic pulmonary fibrosis (IPF).